Overview

Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2031-12-30
Target enrollment:
Participant gender:
Summary
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
Phase:
PHASE4
Details
Lead Sponsor:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.